Clinical Trials Logo

Clinical Trial Summary

This study is designed to determine the maximal tolerated dose of Ruxolitinib in combination with nilotinib in patients with chronic myeloid leukemia (CML).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01702064
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact
Status Completed
Phase Phase 1
Start date February 21, 2013
Completion date January 9, 2019

See also
  Status Clinical Trial Phase
Completed NCT01593254 - Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Phase 2
Recruiting NCT03610971 - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Phase 2
Completed NCT03045120 - Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Recruiting NCT03934372 - Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Phase 1/Phase 2
Completed NCT01850004 - Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Phase 2
Terminated NCT02627677 - A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Phase 3
Completed NCT01660906 - Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Phase 4
Completed NCT01933906 - Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response Phase 1
Completed NCT01914484 - Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Phase 1/Phase 2